Methods for predicting the efficacy of treatment
AssigneeBioarray Genetics, Inc.
InventorsMarcia V. FOURNIER, Katherine J. MARTIN
Life of this patent
Estimating the term…
Abstract
Clinical tests for testing therapeutic sensitivity of cancerous breast tissue and methods and kits for performing the same are described herein. Embodiments of the present invention are directed to methods for predicting the efficacy of treatment of breast cancer. In addition, certain embodiments are directed to a kit for testing therapeutic sensitivity of breast cancer tissue.
Claims16
A method for predicting the efficacy of treatment of breast cancer comprising:
- analyzing an expression profile of marker genes from a cancerous breast tissue;
- and predicting the efficacy of treatment if the expression profile from the cancerous breast tissue matches a predetermined expression profile that indicates a patient will respond to the treatment wherein the marker gene is selected from a group consisting of ASPM, NCAPG, CDKN3, AURKA, FOXM1, CEP55, TNFRSF6B, FGFBP1, CAPRIN2, TUBG1, ZWILCH, RRM2, ACTB, ACTN1, EPHA2, TRIP13, CKS2, VRK1, DUSP4, EIF4A1, SERPINE2, ODC1 and combinations thereof.
A kit for testing therapeutic sensitivity of breast cancer tissue comprising:
- a means for identifying the expression profile of a tissue sample having probes to a specific set of genes or proteins associated with the disease;
- and
- labels, reagents, and other materials or instructions for labeling and preparing reagents and other materials necessary to develop an expression profile of one or more marker genes.
A clinical test for breast cancer comprising a means of detecting an expression pattern of one or more marker genes from diseased tissue of a patient;
- wherein the expression level of at least one gene is modulated compared to other diseased tissue;
- and
- wherein the modulation of at least one gene is indicative of a diseased tissue that is sensitive to a specific therapeutic agent.
A method of identifying a breast cancer patient who is likely to respond to a treatment for breast cancer comprising:
- developing a genetic profile from marker genes from a breast tissue sample;
- and
- identifying a breast cancer patient as likely to respond to a treatment for breast cancer if the expression profile matches a predetermined expression profile that indicates that a patient will respond to the treatment wherein the marker gene is selected from the group consisting of ASPM, NCAPG, CDKN3, AURKA, FOXM1, CEP55, TNFRSF6B, FGFBP1, CAPRIN2, TUBG1, ZWILCH, RRM2, ACTB, ACTN1, EPHA2, TRIP13, CKS2, VRK1, DUSP4, EIF4A1, SERPINE2, ODC1 and combinations thereof.
Dependencies are inferred from the claim text.